<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04860076</url>
  </required_header>
  <id_info>
    <org_study_id>BR00012020</org_study_id>
    <nct_id>NCT04860076</nct_id>
  </id_info>
  <brief_title>Open-label, Uncontrolled, Non-Interventional, Retrospective Study to Evaluate Molecular Determinants of Outcome to the Immune Checkpoint Inhibitors (Anti-PD-1/Anti-PD-L1 Monoclonal Antibodies) Treatment for Solid Tumors</brief_title>
  <official_title>Open-label, Uncontrolled, Non-Interventional, Retrospective Study to Evaluate Molecular Determinants of Outcome to the Immune Checkpoint Inhibitors (Anti-PD-1/Anti-PD-L1 Monoclonal Antibodies) Treatment for Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asylia Diagnostics BV</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Asylia Diagnostics BV</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The recent approval of ICB treatments targeting cytotoxic T-lymphocyte antigen 4 (CTLA-4) and&#xD;
      programmed cell death-1 (PD-1/PD-L1) by the US Food and Drug Administration has offered an&#xD;
      improved treatment chance for a variety of malignant tumors, including those with a&#xD;
      particularly poor prognosis. However, a growing number of studies and case reports show that&#xD;
      immunotherapy may accelerate tumor progression in a significant subset of patients ranging&#xD;
      from 9% to 27% across multiple histologies and lead to so-called hyperprogressive disease&#xD;
      (HPD) that leads to a rapid patient death.&#xD;
&#xD;
      During this NIS study, Asylia Diagnostics aims to fill in the first layer of knowledge&#xD;
      leading to the identification of predictive biomarkers and biological mechanisms that could&#xD;
      be used for the prediction, diagnosis, and treatment of melanoma and NSCLC HPD patients.&#xD;
&#xD;
      The study is a retrospective clinical study. During this study basic historical medical&#xD;
      information and scrolls from FFPE-preserved biopsies taken prior to immunotherapy treatment&#xD;
      will be collected. The nature of the study is not invasive and non interruptive to the&#xD;
      standard of care.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 6, 2020</start_date>
  <completion_date type="Anticipated">June 6, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 6, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>RECIST</measure>
    <time_frame>24 weeks</time_frame>
    <description>Response Evaluation Criteria in Solid Tumours</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PFS</measure>
    <time_frame>24 weeks</time_frame>
    <description>Progression free survival</description>
  </secondary_outcome>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Melanoma</condition>
  <condition>Lung Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>Standard of care</description>
    <other_name>Ipilimumab</other_name>
    <other_name>Nivolumab</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects treated by immune checkpoint inhibitors&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Females and males 18-95 y.o.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 (Karnofsky &gt;/=70%)&#xD;
&#xD;
          -  Histologically or cytologically confirmed melanoma or lung cancer, the grade of the&#xD;
             tumor, diagnosed before enrolment into the study.&#xD;
&#xD;
          -  Treatment with anti-PD1/anti-PD-L1 drugs and anti-PD1/anti-PD-L1 drugs in combinations&#xD;
             with other therapies&#xD;
&#xD;
          -  Subjects may have received any number of prior lines of chemotherapy or targeted&#xD;
             therapies&#xD;
&#xD;
          -  Availability of FFPE tissue samples received prior to any type of antitumor treatment&#xD;
             start&#xD;
&#xD;
          -  Complete medical records (stage, receptors status, demographic data)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Has had chemotherapy, targeted small molecule therapy, or radiation therapy &gt;30 Gray&#xD;
             within 14 days prior to the baseline biopsy or persistent adverse events (AE) related&#xD;
             to prior therapy, which have not recovered (i.e., AEs should be ≤Grade 1 or ≤the value&#xD;
             collected at baseline) from AEs due to a previously administered intervention&#xD;
&#xD;
          -  Any evidence of uncontrolled system pathology, active infections, active bleeding&#xD;
             diathesis, renal graft, hepatitis B, C or HIV.&#xD;
&#xD;
          -  Autoimmune diseases such as Addison's disease, thyroiditis, lupus (SLE), Sjogren's&#xD;
             syndrome, scleroderma, myasthenia gravis, Grave's disease, and Goodpasture's syndrome,&#xD;
             requiring active therapy with corticosteroids. If a patient has been taking steroids,&#xD;
             at least 2 weeks must have passed since the last dose. Patients with a history of&#xD;
             endocrinopathies (e.g. hypothyroidism, adrenal insufficiency, hypopituitarism) are&#xD;
             eligible if they are stable on hormone replacement therapy.&#xD;
&#xD;
          -  Patients with prior splenectomy, ocular melanoma&#xD;
&#xD;
          -  Recent (within 1 year) history of another cancer with the exceptions of non-melanoma&#xD;
             skin cancer, superficial bladder cancer, or localized cervical cancer&#xD;
&#xD;
          -  Pregnant patients&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>95 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Andrey Khmelevskiy, MSc</last_name>
    <phone>+32 492 40 40 24</phone>
    <email>andrey.khmelevskiy@asyliadx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Antwerpen</name>
      <address>
        <city>Edegem</city>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vasiliki Siozopoulou, Dr.</last_name>
      <phone>+32 3 821 37 53</phone>
      <email>Vasiliki.Siozopoulou@uza.be</email>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <reference>
    <citation>Borcoman E, Kanjanapan Y, Champiat S, Kato S, Servois V, Kurzrock R, Goel S, Bedard P, Le Tourneau C. Novel patterns of response under immunotherapy. Ann Oncol. 2019 Mar 1;30(3):385-396. doi: 10.1093/annonc/mdz003.</citation>
    <PMID>30657859</PMID>
  </reference>
  <reference>
    <citation>Champiat S, Besse B, Marabelle A. Hyperprogression during immunotherapy: do we really want to know? Ann Oncol. 2019 Jul 1;30(7):1028-1031. doi: 10.1093/annonc/mdz184.</citation>
    <PMID>31173063</PMID>
  </reference>
  <reference>
    <citation>Champiat S, Ferrara R, Massard C, Besse B, Marabelle A, Soria JC, Ferté C. Hyperprogressive disease: recognizing a novel pattern to improve patient management. Nat Rev Clin Oncol. 2018 Dec;15(12):748-762. doi: 10.1038/s41571-018-0111-2. Review.</citation>
    <PMID>30361681</PMID>
  </reference>
  <reference>
    <citation>Friedman CF, Proverbs-Singh TA, Postow MA. Treatment of the Immune-Related Adverse Effects of Immune Checkpoint Inhibitors: A Review. JAMA Oncol. 2016 Oct 1;2(10):1346-1353. doi: 10.1001/jamaoncol.2016.1051. Review.</citation>
    <PMID>27367787</PMID>
  </reference>
  <reference>
    <citation>Fuentes-Antrás J, Provencio M, Díaz-Rubio E. Hyperprogression as a distinct outcome after immunotherapy. Cancer Treat Rev. 2018 Nov;70:16-21. doi: 10.1016/j.ctrv.2018.07.006. Epub 2018 Jul 18. Review.</citation>
    <PMID>30053725</PMID>
  </reference>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 23, 2021</study_first_submitted>
  <study_first_submitted_qc>April 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 26, 2021</study_first_posted>
  <last_update_submitted>April 23, 2021</last_update_submitted>
  <last_update_submitted_qc>April 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
    <mesh_term>Nivolumab</mesh_term>
    <mesh_term>Ipilimumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

